He Zhanpeng, Cheng Hui, Jia Zhihui, Niu Zimin, Li Yu Ting, Huang Wenyong, Guo Vivian Yawei, Su Zhiran, Xie Yao Jie, Shen Jie, Wang Harry Hx
Shunde Hospital of Southern Medical University (The First People's Hospital of Shunde), Foshan, China.
Liwan Central Hospital of Guangzhou, Guangzhou, China.
J Diabetes Investig. 2025 May;16(5):884-892. doi: 10.1111/jdi.14414. Epub 2025 Feb 1.
To assess the extent to which biomedical outcomes and cardiovascular risk profile were improved in the management of Chinese patients with type 2 diabetes enrolled in the metabolic management center (MMC) program.
We performed propensity score matching of diabetic patients in the MMC program for at least 12 months to those with diabetes under usual primary care, based on age, sex, fasting plasma glucose (FPG) level, and diabetes duration. Difference-in-difference analysis was conducted to compare changes in biomedical outcomes, attainment of treatment targets, and cardiovascular disease (CVD) risk reduction.
Of 557 pairs of diabetic patients matched 1:1 (n = 1,114), the MMC cohort exhibited greater improvements in FPG (-0.84 mmol/L, 95% confidence interval [CI] -1.22 to -0.46, P < 0.001), diastolic blood pressure [BP] (-2.08 mmHg, 95%CI -3.21 to -0.94, P < 0.001), body mass index [BMI] (-0.29 kg/m, 95%CI -0.51 to -0.07, P = 0.009), low-density lipoprotein cholesterol (0.13 mmol/L, 95%CI 0.04-0.23, P = 0.008), high-density lipoprotein cholesterol (0.05 mmol/L, 95%CI 0.01-0.08, P = 0.017), and 10-year CVD risk (Framingham CVD risk, -0.94%, 95%CI -1.71 to -0.17, P = 0.017; atherosclerotic CVD risk, -0.77%, 95%CI -1.34 to -0.20, P = 0.009) when compared to the usual primary care cohort after adjustment for confounders. More patients in the MMC cohort achieved treatment targets with lifestyle modifications than their counterparts under primary care.
Enrolment in the MMC program appears promising in the management of FPG, BP, BMI, lifestyle, and CVD risk in diabetic patients, suggesting the necessity of incorporating the MMC program into routine primary care.
评估参加代谢管理中心(MMC)项目的中国2型糖尿病患者在管理过程中生物医学指标和心血管风险状况的改善程度。
我们根据年龄、性别、空腹血糖(FPG)水平和糖尿病病程,对MMC项目中至少参加12个月的糖尿病患者与接受常规初级保健的糖尿病患者进行倾向得分匹配。采用差分分析比较生物医学指标的变化、治疗目标的达成情况以及心血管疾病(CVD)风险的降低情况。
在1:1匹配的557对糖尿病患者(n = 1114)中,调整混杂因素后,与常规初级保健队列相比,MMC队列的FPG(-0.84mmol/L,95%置信区间[CI]-1.22至-0.46,P < 0.001)、舒张压[BP](-2.08mmHg,95%CI-3.21至-0.94,P < 0.001)、体重指数[BMI](-0.29kg/m²,95%CI-0.51至-0.07,P = 0.009)、低密度脂蛋白胆固醇(0.13mmol/L,95%CI 0.04 - 0.23,P = 0.008)、高密度脂蛋白胆固醇(0.05mmol/L,95%CI 0.01 - 0.08,P = 0.017)以及10年CVD风险(弗雷明汉CVD风险为-0.94%,95%CI-1.71至-0.17,P = 0.017;动脉粥样硬化性CVD风险为-0.77%,95%CI-1.34至-0.20,P = 0.009)有更大改善。与初级保健组相比,MMC队列中有更多患者通过生活方式改变达到了治疗目标。
参加MMC项目在糖尿病患者的FPG、BP、BMI、生活方式和CVD风险管理方面似乎很有前景,这表明有必要将MMC项目纳入常规初级保健。